Circular mRNA against Clean Cap linear mRNA vectors comprehensive comparison, expression, active and passive immunization
Vakhtinskii, V. M.; Tutykhina, I. L.; Dzharullaeva, A. S.; Grousova, D. M.; Zorkov, I. D.; Ilyukhina, A. A.; Reshetnikov, D. A.; Azizyan, V. V.; Derkaev, A. A.; Bykonia, E. N.; Usachev, E. V.; Kleymenov, D. A.; Gushchin, V. A.; Dolzhikova, I. V.; Shcheblyakov, D. V.; Shmarov, M. M.; Logunov, D. Y.; Gintsburg, A. L.
Show abstract
The mRNA platform has revolutionised vaccine technology by providing a universal, fast and easily scalable production process. There are two main types of mRNA - linear (cap-dependent) and circular (cap-independent), each with its own advantages. Although both vector types are continuously being improved, there has been no comprehensive comparative analysis of the most efficient existing vectors of each type. This paper provides a comparison of expression efficiency, protective and therapeutic activities of circular and linear mRNA vectors. We examined different combinations of linear vectors: containing either N1-methylpseudouridines or uridine and capped with either ARCA (m7G(5')ppp(5')G) or CleanCap (m7G(5')ppp(5')m2G). Circular vectors contained both commonly used IRES of coxsackievirus B3 and new a IRES of human rhinoviruses B6. Preliminary luciferase assay showed that modified linear vectors exhibited significantly higher expression levels both in vitro and in vivo. A similar but less dramatic difference was observed in expression of the target protein. At the same time, immunogenicity and protective activity of linear and circular vectors were equal.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine 95%
- Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2 95%
- A Scalable Topical Vectored Vaccine Candidate Against SARS-CoV-2 95%
Similar papers in this journal
- The chicken chorioallantoic membrane model for isolation of CRISPR/cas9-based HSV-1 mutant expressing tumor suppressor p53 95%
- In silico analysis and in planta production of recombinant ccl21/IL1β protein and characterization of its in vitro anti-tumor and immunogenic activity 95%
- Design of multi-epitope vaccine candidate against Brucella type IV secretion system (T4SS) 94%
Similar papers in this journal
- Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models 97%
- Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates 96%
- Recombinant SARS-CoV-2 RBD molecule with a T helper epitope as a built in adjuvant induces strong neutralization antibody response 95%
Similar papers in this journal
- Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice 97%
- Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19 95%
- Novel Peptide Inhibitor of Human Tumor Necrosis Factor-α has Antiarthritic Activity 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.